Clinical Trials Logo
  1. Home
  2. Severe Eosinophilic Asthma
  3. NCT03739320

A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma

Severe Eosinophilic Asthma Clinical Trial

Official title:
A Prospective Observational Study on the Effect of Mepolizumab add-on Therapy on Daily Physical Activity in Patients With Severe Eosinophilic Asthma

Clinical Trial Summary

Daily physical activity in adult patients with asthma remains overlooked. Limited evidence demonstrates reduced levels of daily physical activity in asthma populations but studies examining the potential effect of available therapies are missing. This study aims to investigate the overall levels of daily physical activity in patients with severe eosinophilic asthma and whether anti-interleukin-5 therapy with mepolizumab, on top of existing, maximal, and optimised asthma treatment, may improve patient's daily physical activity.

Clinical Trial Description

A multi-centre, prospective, observational study of continuous patients who fulfil the definition of severe asthma and the criteria for mepolizumab (nucala; GSK) therapy. Patients have their daily physical activity recorded using triaxial accelerometry (DynaPort MoveMonitor; McRoberts) prior to treatment, and at 6 and 12 months of mepolizumab therapy (100 mg subcutaneously once every 4 weeks). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03739320
Study type Observational
Source Sotiria General Hospital
Contact Marios Panagiotou, MD
Phone +306974238267
Email mpanagiotou@med.uoa.gr
Status Recruiting
Phase
Start date December 11, 2017
Completion date December 31, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Completed NCT02560610 - Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Phase 2
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Not yet recruiting NCT03652376 - Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Phase 4
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Completed NCT05180357 - RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Active, not recruiting NCT03833141 - Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
Completed NCT05271526 - Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Not yet recruiting NCT06302959 - Clock Proteins as Prognostic Markers
Recruiting NCT05440656 - A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
Completed NCT04159519 - A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Phase 4
Completed NCT03907137 - Real World Study With Benralizumab in Severe Asthma in Switzerland
Active, not recruiting NCT04084613 - Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
Completed NCT04126499 - Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Recruiting NCT06465485 - STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Phase 3